Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Dec;16(12):3455-62.
doi: 10.1245/s10434-009-0629-8.

S-100B concentrations predict disease-free survival in stage III melanoma patients

S Kruijff  1 , E Bastiaannet, A C Muller Kobold, R J van Ginkel, A J H Suurmeijer, H J Hoekstra
Affiliations

S-100B concentrations predict disease-free survival in stage III melanoma patients

S Kruijff et al. Ann Surg Oncol. 2009 Dec.

Erratum in

  • Ann Surg Oncol. 2011 Dec;18 Suppl 3:S331

Abstract

Background: Elevation of the tumor marker S-100B in melanoma patients is a highly specific indicator of recurrence.

Materials and methods: The role of S-100B in disease-free survival (DFS) was evaluated in stage III melanoma patients (staged with fluorodeoxyglucose positron emission tomography [FDG-PET] and computed tomography [CT]) with palpable lymph node metastases who underwent therapeutic lymph node dissection. S-100B and LDH were measured on the day before surgery (d = -1) and on days 1, 2, and 7 postoperatively. Multivariate logistic regression was used to study factors associated with preoperative elevation of S-100B. Univariate (log-rank test) and multivariate (Cox regression) survival analyses were performed to identify factors associated with DFS.

Results: Between 2004 and 2008, 56 patients (median age 57, range 24-93) years, 27 males (48%) and 29 females (52%) entered the study. Preoperative S-100B elevation was found in 27 patients (48%) and elevated LDH in 20 patients (36%). No association was found between these two markers at any time. Multivariate analysis showed that elevated S-100B preoperatively (hazard ratio [HR] 2.7, P = .03) was associated with DFS. S-100B elevation was associated with increased tumor size (odds ratio [OR] 3.40; P = .03).

Conclusion: Elevated S-100B preoperatively in patients with optimally staged clinical stage III melanoma is associated with decreased disease-free survival. S100-B could be used as a prognostic marker in the stratification of new adjuvant trials to select stage III melanoma patients for adjuvant systematic treatment.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan-Meier curve for preoperative S-100B and disease-free survival of AJCC stage III melanoma patients. a Elevated preoperative S-100B (34% 2-year DFS) versus not elevated (61% 2-year DFS) levels are associated with a decreased disease-free survival (P = .03). b Increasing postoperative S-100B levels (30% 2-year DFS) versus not increasing (51% 2-year DFS) (P = .1)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siesling S, Visser O, van Dijck JA, Coebergh JW. Trends in the incidence and death from cancer from 1989–2003 in The Netherlands. Ned Tijdschr Geneeskd. 2006;150:2490–2496. - PubMed
    1. Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res. 2007;17:117–127. doi: 10.1097/CMR.0b013e328042bb36. - DOI - PubMed
    1. Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol. 2005;6:608–621. doi: 10.1016/S1470-2045(05)70283-7. - DOI - PubMed
    1. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–1317. doi: 10.1056/NEJMoa060992. - DOI - PubMed
    1. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients. Validation of the American Joint Committee on Cancer melanoma system. J Clin Oncol. 2001;19:3622–3634. - PubMed

MeSH terms